Exabis Library
Welcome to the e-CCO Library!
P580: Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P580: Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P580: Vitamin D substitution dose in IBD patients: Higher than recommended?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P581 Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: First real-life experiences
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P581: Complementary and alternative therapies for inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P581: Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn's disease: European multicentre study with a propensity-score matched analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P581: Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P581: Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P581: Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P582: Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P582: Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P582: Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P582: Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P582: Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P583 The prevalence of side effects to immunomodulators and biologics in patients with Crohn’s disease intestinal failure compared with Crohn’s disease without intestinal failure
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P583: Efficacy of vedolizumab (VDZ) by disease extension in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM